Jyong Biotech (MENS) Non-Current Debt (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Non-Current Debt of $447000.0 for Q4 2025, down 78.0% year-over-year from $2.0 million in Q4 2024, and down 77.02% quarter-over-quarter from $1.9 million in Q2 2025.
Jyong Biotech (MENS) Non-Current Debt (2024 - 2025) Analysis & Trends
Jyong Biotech's Non-Current Debt history runs 2 years deep, the most recent figure standing at $447000.0 for Q4 2025.
- In Q4 2025, Non-Current Debt fell 78.0% year-over-year to $447000.0; the TTM figure through Dec 2025 stood at $447000.0 (down 78.0% YoY), while the FY2025 annual figure was $447000.0, down 78.0% from the prior year.
- Non-Current Debt for Q4 2025 stood at $447000.0, down from $1.9 million in the prior quarter.
- The five-year high for Non-Current Debt was $2.0 million in Q4 2024, with the low at $447000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Jyong Biotech | 159.89 Mn | 159.89 Mn | - | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 447,000.00 |
| Jun 30, 2025 | 1.95 Mn |
| Dec 31, 2024 | 2.03 Mn |